First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer - interview with Ken Kato

from Medical Digest & Congress Report · host Medical Congress News

Professor Ken Kato gave us a talk about longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study. Video: https://congressreport.eu/scientific-contents/standalonecontent:first-line-pembrolizumab-plus-chemotherapy-versus-chemotherapy-advanced-esophageal-cancer

Episode metadata supplied by the publisher feed · Published Mar 1, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer - interview with Ken Kato

0:00 7:39

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 7 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on March 1, 2022.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!